Introduction
Sensory symptoms related to pain perception have been reported to occur in 30-50% of parkinsonian patients (Coyle & Snyder, 1969) . In the majority of cases, patients experienced recurrent pain and other abnormal sensations that could not be attributed directly to disorders ofthe musculoskeletal or vascular systems. Furthermore, these abnormal sensations did not appear to be related to the presence of the motor disabilities such as rigidity or tremor (Snider et al., 1976) . It is thus believed that the abnormal sensory phenomena experienced by these patients were caused primarily by the disease process itself, and were not secondary to any of the motor malfunctions of the disease.
The pathogenesis of the abnormal sensory symptoms experienced by some parkinsonian patients is not well understood. Nutt & Carter (1984) have recently suggested a role for the dopaminergic system in the pathogenesis of these symptoms. Administration of Ldopa during the 'off' period produced amelioration of distressing sensory phenomena in 2 patients with Parkinson's disease, while Snider et al., (1976) and Sandyk (1982) reported amelioration of sensory phenomena with oral narcotic analgesics. The latter reports suggested a role for the endogenous opioid system in the pathogenesis of primary sensory symptoms in parkinsonism (Sandyk & Snider, 1985) . The report by Snider et al. (1976) suggested, however, that not all cases of parkinsonism with abnormal sensory disturbances respond to either dopaminergic drugs or opiates, indicating a role for other transmitter systems in the pathogenesis of abnormal sensory phenomena in Parkinson's disease. The following report concerns 2 patients who experienced abnormal sensory phenomena related primarily to pain, in whom administration of anticholinergics (benzhexol) produced dramatic relief of symptomatology.
Case reports
Case I A 54 year old man presented with generalized pain of 12 months duration. The pain was described as dullaching and at times burning and involved predominantly the trunk, the lower back and muscles and joints of both upper extremities. These sensations were present throughout the day and night, were unrelated to movement, and were not relieved by standard analgesics, non-steroidal anti-inflammatory drugs or physical therapy. General examination was unremarkable. Neurological assessment revealed no evidence for musculoskeletal disease. However, he had some mild stigmata of parkinsonism that included facial amimia, positive glabellar tap, decreased arm swing, and mild hypokinesia and right-sided upper limb rigidity. The rest of the examination was normal. Laboratory investigations, including serum bio- (Koller, 1984; Schott, 1985) painful sensory phenomena antedated or were present at the initial stages of the disease. These sensory disturbances improved occasionally with dopamine agonists but many patients experienced no relief with a variety of agents (Snider et al., 1976) .
The mechanism(s) by which dopaminergic agents produced alleviation of painful sensory symptoms in parkinsonism are not understood. Dopamine has been shown to play a role in pain suppression (Akil & Liebeskind., 1975) and to be efficacious in the therapy of pain in herpes zoster (Kernbaum & Hauchecorne, 1981) and cancer (Minton, 1974) . Our patients failed, however, to respond to levodopa although other features oftheir motor disability improved, suggesting that the painful sensations were unrelated to the motor disability. Furthermore, their symptoms were resistent to administration of oral analgesics and non-steroidal anti-inflammatory drugs, suggesting a role for nonopioid mediated mechanisms in the pathophysiology of painful sensations in Parkinson's disease. The patient's dramatic response to benzhexol indicates a role for the cholinergic system in human analgesia. Indeed, the cholinergic system has been suggested to be involved in analgesia induced by morphine (Domino, 1975) and has also been implicated in modulating stress-induced analgesia in animals (Lewis & Liebeskind, 1983) . Furthermore, involvement of cholinergic mechanisms in certain human pain states has also received some support from a recent report demonstrating that anticholinesterase drugs are useful in the management of chronic pain (Schott & Loh, 1984) . Paradoxically, however, our patients experienced pain relief with anti-cholinergic medication.
Anti-cholinergic agents have been shown to be efficacious in the management of motor symptoms in Parkinson's disease. Apart from reducing the functional overactivity of cholinergic interneurones in the striatum, these agents have been shown to increase striatal dopamine levels by inhibiting dopamine reuptake (Coyle et al., 1969) . However, since our patient's painful sensory phenomena failed to respond to Sinemet, it seems unlikely that the analgesic effects of benzhexol were mediated via dopaminergic mechanisms. Whatever the mechanism(s) of benzhexol-induced analgesia may be, this report indicates a complex function of the cholinergic system in pain control and in the pathophysiology of abnormal sensory phenomena in Parkinson's disease.
